Efficacy and safety of GSK1358820 in subjects with overactive bladder

Trial Identifier: 204947
Sponsor: GlaxoSmithKline
Start Date: August 2016
Primary Completion Date: March 2018
Condition: Bladder Disease

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Japan Aichi, Japan, 474-8511
Japan Aichi, Japan, 466-8560
Japan Chiba, Japan, 264-0017
Japan Chiba, Japan, 270-0034
Japan Chiba, Japan, 270-1694
Japan Fukui, Japan, 910-1193
Japan Fukuoka, Japan, 816-0943
Japan Fukuoka, Japan, 810-0001
Japan Fukuoka, Japan, 815-8588
Japan Fukuoka, Japan, 802-8517
Japan Fukuoka, Japan, 814-0022
Japan Gifu, Japan, 502-8511
Japan Hokkaido, Japan, 060-8648
Japan Ibaraki, Japan, 309-1793
Japan Ibaraki, Japan, 310-0011
Japan Ishikawa, Japan, 920-8641
Japan Kagoshima, Japan, 890-0073
Japan Kagoshima, Japan, 890-8520
Japan Kanagawa, Japan, 252-0392
Japan Kanagawa, Japan, 231-0861
Japan Kanagawa, Japan, 227-8501
Japan Kyoto, Japan, 612-8555
Japan Miyagi, Japan, 980-0803
Japan Miyagi, Japan, 981-0501
Japan Nagasaki, Japan, 852-8501
Japan Niigata, Japan, 950-8725
Japan Okayama, Japan, 710-8522
Japan Okayama, Japan, 700-8558
Japan Osaka, Japan, 542-0086
Japan Osaka, Japan, 564-0013
Japan Osaka, Japan, 554-0012
Japan Shiga, Japan, 520-2192
Japan Shizuoka, Japan, 431-3192
Japan Tochigi, Japan, 321-0293
Japan Tokushima, Japan, 770-8503
Japan Tokyo, Japan, 173-8610
Japan Tokyo, Japan, 164-8541
Japan Tokyo, Japan, 116-8567
Japan Tokyo, Japan, 181-8611
Japan Tokyo, Japan, 135-8577
Japan Tokyo, Japan, 162-8655
Japan Tokyo, Japan, 113-8655
Japan Tokyo, Japan, 101-8309
Japan Tottori, Japan, 683-8504
Japan Tottori, Japan, 680-0903
Japan Toyama, Japan, 937-0042
Japan Yamagata, Japan, 990-0834
Japan Yamanashi, Japan, 409-3898